| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | AMT |
| Uniprot No | P48728 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-403aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSAQEVLRRTPLYDFHLAHGGKMVAFAGW SLPVQYRDSHTDSHLHTRQHCSLFDVSHMLQTKILGSDRVKLMESLVVGD IAELRPNQGTLSLFTNEAGGILDDLIVTNTSEGHLYVVSNAGCWEKDLAL MQDKVRELQNQGRDVGLEVLDNALLALQGPTAAQVLQAGVADDLRKLPFM TSAVMEVFGVSGCRVTRCGYTGEDGVEISVPVAGAVHLATAILKNPEVKL AGLAARDSLRLEAGLCLYGNDIDEHTTPVEGSLSWTLGKRRRAAMDFPGA KVIVPQLKGRVQRRRVGLMCEGAPMRAHSPILNMEGTKIGTVTSGCPSPS LKKNVAMGYVPCEYSRPGTMLLVEVRRKQQMAVVSKMPFVPTNYYTLK |
| 预测分子量 | 43 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AMT重组蛋白的3篇参考文献示例，内容基于学术文献的典型结构模拟：
---
1. **文献名称**：*Enhanced Recombinant Protein Production in Yeast via AMT-Based Expression Systems*
**作者**：Chen Y., Wang T., Li X.
**摘要**：本研究利用AMT(Advanced Modular Technology)平台优化酵母表达系统，通过模块化载体设计和代谢通路调控，显著提高重组蛋白(如抗体片段)的产量和折叠效率，为工业化生产提供新策略。
2. **文献名称**：*Agrobacterium-Mediated Transformation (AMT) for Recombinant Protein Biosynthesis in Plant Hairy Roots*
**作者**：Gomez-Roldan M.V., et al.
**摘要**：探讨农杆菌介导转化(AMT)技术在植物毛状根中生产药用重组蛋白(如疫苗抗原)的应用，证明其具备成本低、易规模化的优势，并分析了表达水平的关键影响因素。
3. **文献名称**：*AMT-Driven Secretion Engineering in Bacillus subtilis for Improved Recombinant Protein Yield*
**作者**：Kuroda K., Ueda M.
**摘要**：通过AMT(Adaptive Microbial Tailoring)技术改造枯草芽孢杆菌的分泌途径，增强重组酶和疫苗蛋白的胞外分泌效率，减少包涵体形成，提升下游纯化效率。
---
**备注**：AMT在不同文献中可能指代不同技术(如Advanced Modular Technology、Agrobacterium-Mediated Transformation等)，需结合具体研究背景理解。实际引用时建议核实文献原文。
**Background of AMT Recombinant Proteins**
Recombinant proteins, engineered through genetic modification, are produced by inserting target DNA into host organisms (e.g., bacteria, yeast, or mammalian cells) to express specific proteins. AMT (Advanced Molecular Technology) recombinant proteins represent a cutting-edge subset of this field, leveraging optimized expression systems, purification techniques, and bioengineering strategies to enhance protein yield, stability, and functionality.
The development of AMT recombinant proteins is driven by their critical roles in biomedical research, therapeutics, and industrial applications. For instance, they are widely used in drug development (e.g., monoclonal antibodies, vaccines), diagnostic tools (e.g., enzyme-linked immunosorbent assays), and as research reagents to study cellular mechanisms. Traditional recombinant protein production often faces challenges like low expression levels, misfolding, or post-translational modification inefficiencies. AMT approaches address these by employing tailored host systems (e.g., CHO cells for complex glycosylation) and advanced gene-editing tools (e.g., CRISPR) to optimize expression vectors.
Recent advancements in AMT focus on scalability and cost-effectiveness, particularly for therapeutic proteins. Innovations include continuous bioprocessing, cell-free synthesis, and AI-driven protein design. These technologies aim to accelerate production timelines while maintaining high purity and bioactivity. Additionally, AMT platforms are increasingly used to produce proteins for personalized medicine, such as cancer-targeting biologics or enzymes for rare genetic disorders.
Despite progress, challenges persist, including ensuring batch-to-batch consistency, managing immunogenicity, and meeting regulatory standards. Ongoing research emphasizes sustainable production methods and novel delivery systems (e.g., nanoparticle carriers) to expand clinical applications. As demand for precision biologics grows, AMT recombinant proteins remain pivotal in bridging the gap between laboratory discovery and real-world therapeutic solutions.
×
